Abstract
The history of treatment of Gaucher disease started with splenectomy and continued with bone marrow transplantation, before the recent introduction of enzyme replacement therapy. Although the latter has revolutionized the prognosis of patients, many questions remain to be answered and clinical management problems resolved. These include how to monitor enzyme replacement to determine the optimal dosage, how to treat mild disease, whether intermittent treatment is an option, and the causes of the neurological signs and how to treat them. The pulmonary hypertension problem has also not been resolved, and we need to determine how to treat and monitor bone disease. In addition, the future role of substrate deprivation needs to be determined, and further research is required before gene therapy becomes a potential clinical option. The high cost of enzyme replacement treatment for Gaucher disease remains an important issue.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Ashkenazi A, Zaizov R, Matoh Y (1986) Effect of splenectomy on destructive bone changes in children with chronic (type I) Gaucher disease. Eur J Pediatr 145: 138–141.
Barranger JA, Rice EO, Swaney WP (1999) Gene transfer approaches to the lysosomal storage disorders. Neurochem Res 24: 601–615.
Barranger JA (2000) Gene transfer strategies for Gaucher disease. Abstract, 4th Meeting of the European Working Group on Gaucher Disease, Jerusalem.
Barton NW, Brady RO, Dambrosia J (1991a) Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324: 1464–1470.
Barton NW, Brady RO, Murray GJ, et al (1991b) Enzyme-replacement therapy for Gaucher's disease: Reply. N Engl J Med 325: 1811.
Beighton P, Goldblatt J, Sacks S (1982) Bone involvement in Gaucher disease. In Desnick RJ, Gatts S, Grabowski GA, eds. Gaucher Disease: A Century of Delineation and Research. New York: Alan R Liss, 107–129.
Bembi B, Agosti E, Boehm P, et al (1994) Aminohydroxypropylidene-biphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3. Acta Paediatr 83: 122–124.
Bembi B, Ciana G, Zanatta M, et al (1995) Cerebrospinal fluid infusion of alglucerase in the treatment of acute neuronopathic Gaucher's disease. Pediatr Res 38: 425.
Beutler E (1997) Enzyme replacement therapy for Gaucher disease. Baillieres Clin Haematol 10: 751–763.
Beutler E, Kay A, Saven A, et al (1991) Enzyme replacement therapy for Gaucher disease. Blood 78: 1183–1189.
Cox T, Lachmann R, Hollak C, et al (2000) Novel oral treatment of Gaucher's disease with Nbutyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355: 1481–1485.
Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A (2000) Withdrawal of enzyme replacement therapy in Gaucher's disease. Br J Haematol 110: 488–492.
Elstein D, Hadas-Halpern I, Itzchaki M, et al (1996) Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis 22: 104–111.
Erikson A (1986) Gaucher disease-Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment. Acta Paediatr Scand 326: 1–42.
Erikson A, Åström M, Månsson JE (1995) Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease. Neuropediatrics 26: 203–207.
Erikson A, Johansson K, Månsson JE, Svennerholm L (1993) Enzyme replacement therapy of infantile Gaucher disease. Neuropediatrics 24: 237–238.
Harats D, Pauzner R, Elstein D, et al (1997) Pulmonary hypertension in two patients with type 1 Gaucher disease while on alglucerase therapy. Acta Haematol (Basel) 98: 47–50.
Hobbs JR, Jones KH, Shaw PJ, Lindsay I, Hancock M (1987) Beneficial effects of pre-transplant splenectomy on displacement bone marrow transplantation for Gaucher's syndrome. Lancet i: 1111–1115.
Kerem E, Elstein D, Abrahamov A, et al (1996) Pulmonary function abnormalities in type 1 Gaucher disease. Eur J Resp Dis 9: 340–345.
Orvisky E, Sidransky E, McKinney CE, et al (2000) Glucosylsphingosine accumulation in mice and patients with Gaucher disease begins early in gestation. Pediatr Res 48: 233–237.
Pelini M, Boice D, O'Neil K, et al (1994) Glucocerebrosidase treatment of type I Gaucher disease with severe pulmonary involvement. Ann Int Med 121: 196–197.
Ringdén O, Groth CG, Erikson A, Granqvist S, Månsson JE, Sparrelid E (1995) Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation 59: 125–133.
Rosenthal DL, Doppelt SH, Mankin HJ, et al (1995) Enzyme replacement therapy for Gaucher disease: skeletal response to macrophage-targeted glucocerebrosidase. Pediatrics 96: 629–636.
Rubin M, Yampolski Y, Lambroso L, Zaizov R, Dintsman M (1986) Partial splenectomy in Gaucher disease. J Pediatr Surg 21: 125–128.
Samuel R, Katz K, Papapoulus S, et al (1994) Aminohydroxypropylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics 94: 385–389.
Schiffmann R, Heyes MP, Aerts JM, et al (1997) Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher disease. Ann Neurol 42: 613–621.
Vellodi A, Bembi B, de Villemeur TB, et al (2001) Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 24: 319–327.
Zimran A, Elstein D, Levy-Lahad E, et al (1995) Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 345: 1479–1480.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Erikson, A. Remaining problems in the management of patients with Gaucher disease. J Inherit Metab Dis 24 (Suppl 2), 122–126 (2001). https://doi.org/10.1023/A:1012452715079
Issue Date:
DOI: https://doi.org/10.1023/A:1012452715079